Transcenta Holding Ltd
Company Profile
Business description
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capacities in discovery, research, development, manufacturing, and business development. It is developing approximately fifteen therapeutic antibody molecules for oncology and selected non-oncology indications, including bone and kidney disorders. The company's drug development pipeline includes Osemitamab (TST001), TST002 (Blosozumab), TST003, TST006, MSB2311, MSB0254, TST808, and others to treat various oncology and non-oncology complications in different ways. Geographically, the company operates in China (the PRC), which is its key revenue market, and the United States of America.
Contact
218 Xinghu Street
B6-501, Biobay
Suzhou215123
CHNT: +86 51267079200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
184
Stocks News & Analysis
stocks
Telstra earnings: No need to get hysterical over mobile
stocks
Market Minute: RBA cuts rates again, US CPI data released
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,233.50 | 21.40 | 0.23% |
| CAC 40 | 7,884.05 | 39.40 | -0.50% |
| DAX 40 | 24,314.77 | 44.53 | -0.18% |
| Dow JONES (US) | 44,911.82 | 34.30 | -0.08% |
| FTSE 100 | 9,157.74 | 18.84 | 0.21% |
| HKSE | 25,176.85 | 93.22 | -0.37% |
| NASDAQ | 21,629.77 | 6.80 | 0.03% |
| Nikkei 225 | 43,714.31 | 336.00 | 0.77% |
| NZX 50 Index | 12,970.64 | 81.26 | 0.63% |
| S&P 500 | 6,449.15 | 0.65 | -0.01% |
| S&P/ASX 200 | 8,959.30 | 20.70 | 0.23% |
| SSE Composite Index | 3,728.03 | 31.26 | 0.85% |